<DOC>
	<DOCNO>NCT01856803</DOCNO>
	<brief_summary>Age risk factor graft-versus-host disease ( GVHD ) human leukocyte antigen ( HLA ) -matched sibling allogeneic stem cell transplantation ( allo-SCT ) . The incidence acute GVHD significantly high patient 40 year age 18 39 year age allo-SCT . It find Anti-thymocyte globulin use prophylaxis acute chronic GVHD allo-SCT.Prophylaxis GVHD use ATG patient 40 year age match sibling allo-SCT setting might significantly decrease incidence acute chronic GVHD incidence late effect transplantation .</brief_summary>
	<brief_title>Anti-thymocyte Globulins Graft-versus-host Disease Prophylaxis</brief_title>
	<detailed_description>Prophylaxis GVHD include CSA , MTX MMF±ATG . In trial group , CSA start intravenously day -1 , dosage 3 mg/kg , switch oral formulation soon patient able take medication engraftment . The dosage adjust maintain trough blood level 200-300ng/ml . MMF administer orally , 0.25g every 12 hour , day -1 transplantation day 30 transplantation . The dosage MTX 15 mg/m2 , administer i.v . day 1 , 10 mg/m2 day 3 , 6 , 11 transplantation . ATG ( Thymoglobulin 2.5mg/kg per day i.v . ) day -2 -1 . In control group , CSA start intravenously day -1 , dosage 3 mg/kg , switch oral formulation soon patient able take medication engraftment . The dosage adjust maintain trough blood level 200-300ng/ml . MMF administer orally , 0.25g every 12 hour , day -1 transplantation day 30 transplantation . The dosage MTX 15 mg/m2 , administer i.v . day 1 , 10 mg/m2 day 3 , 6 , 11 transplantation .</detailed_description>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<criteria>Standardrisk recipient hematological malignancy ( include AMLCR1 , ALLCR1 , CMLCP , MDSRA , RARS , RCMD , RAEB1 ) ; age 40 60 ; HLAmatched sibling donor ; Eastern Cooperative Oncology Group ( ECOG ) ≤1 , ejection fraction ( EF ) ≥50 % ; bilirubin≤35µmol/L ; AST , ALT low equall twofold baseline ; creatinie≤130µmol/L . Active , uncontrolled infection ; severe allergy ATG , include shock laryngeal edema ; secondary stem cell transplant recipient ; haplidentical recipient ; match unrelated donor recipient ; nonmyeloablative condioning regimen recipient ; EF &lt; 50 % ; bilirubin &gt; 35µmol/L ; AST , ALT high twofold baseline ; creatinie &gt; 130µmol/L .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>